Jazz Pharmaceuticals (NASDAQ:JAZZ) Downgraded by StockNews.com

StockNews.com lowered shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) from a strong-buy rating to a buy rating in a report released on Friday morning. A number of other equities research analysts also recently issued reports on the company. Needham & Company LLC lowered their price target on Jazz Pharmaceuticals from $210.00 to $205.00 and […]

Related Keywords

Wellington ,New Zealand General ,New Zealand ,Blackrock ,Brucec Cozadd ,Finbar Larkin ,Goldman Sachs Group ,Hedge Funds Weigh In On Jazz Pharmaceuticals ,Blackrock Inc ,Wellington Management Group ,Jazz Pharmaceuticals ,Jazz Pharmaceuticals Plc ,Analyst Recommendations For Jazz Pharmaceuticals ,News Ratings For Jazz Pharmaceuticals Daily ,Needham Company ,Jazz Pharmaceuticals Price Performance ,Vanguard Group Inc ,Get Rating ,Moderate Buy ,Management Group ,Street Corp ,Pharmaceuticals Plc ,Jazz Pharmaceuticals Daily ,Nasdaq Jazz ,Jazz ,Medical ,G5087110 ,Downgrade ,Stocknews Com ,